Medpace Logo

For Immediate Release: October 14, 2019

Julie Hopkins
513-579-9911 x 12627

Medpace Announces Expanding Molecular and Genetic Laboratory Capabilities in Belgium

Dr. Fary Diop Joins Medpace to Provide Leadership in Molecular Capabilities Expansion in Belgium

Leuven, BE — (OCTOBER, 14 2019) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO) known for its strong therapeutic and regulatory expertise, announced that it is expanding its molecular and genetic testing capabilities in Belgium. A new building has recently been added in the Leuven facility that will host a state-of-the-art molecular suite complemented with a dedicated tissue culture room. In addition, a molecular scientist, Dr. Fary Diop, has joined Medpace Belgium to provide leadership in building the molecular capabilities, with support from Dr. El Mustapha Bahassi from Medpace’s US molecular laboratory.

With the advancement of precision medicine, molecular and genetic testing is becoming a critical component for patient selection and individual assessment of the risks and benefits of treatment. The build-out of our molecular suite in Belgium will further enhance our ability to support sponsors with advanced testing to detect pathogenic events at the genome level.

Highlights of the Molecular Suite Expansion – Bringing Science and State-of-the-Art Capabilities to Innovative Clinical Development

A new building was built in the Leuven facility to accommodate a completely re-invented laboratory. The new molecular area is designed with engineering and procedural controls to minimize risk of reagent and sample contamination including: private access, bi-directional airflow / pressure control, and environmental monitoring system. The laboratory is currently equipped with the capability for DNA and RNA extraction and viral load quantification using the Abbott m2000 system.

Within the upcoming year, Medpace’s central laboratory in Belgium will expand its capabilities and cross-validate a large number of automated and manual tests already provided by the US molecular lab. These tests include tissue culture, Sanger sequencing and next generation sequencing. The cross-validation will also include a large menu of companion diagnostics, pharmacogenomics testing, HLA typing, custom and comprehensive cancer panels for both solid tumors and hematological malignancies, and new biomarkers to predict response to immuno-therapy. Additionally, Medpace will continue to work with clients on developing assays for novel biomarkers.

Features of the Belgium Lab Expansion

  • 2,300 square meters (SQM) – 300% increase from old lab
  • Three room molecular suite 85.0 square meters
  • Cell culture room
  • Dedicated flow cytometry bay with 4C and RT working capacity and dual-cytometer platforms
  • BD FACS Canto IVD 10-color with high-throughput sampler, BD FACSLyric IVD 10-color platform with high-throughput sampler
  • Biorepository increased from 86 SQM to 800 SQM (includes liquid nitrogen storage)
  • Logistics/Kit building increased from 450 SQM to 891 SQM
  • 600 SQM warehouse space
  • Conveyor belt automation in Sample Management to expedite movements and shipments
  • New dry ice packing machine that will automate the process of dry ice shipments

Expanded Assays Capabilities in Belgium

  • Absolute cell enumeration
  • CAR-T cell analysis
  • Custom cell-mediated assays
  • Epigenetic profiling of immune subsets
  • Fetal hemoglobin assays
  • Immunophenotyping
  • In vitro stimulation assays
  • Intracellular Staining Assays (ICS)
  • MACS based cell separation with purity report
  • PNH Type III analysis
  • Rare event enumeration
  • Receptor Occupancy Assays
  • Stem cell enumeration
  • T cell, NK cell activations panels

About Dr. Fary Diop

Dr. Fary Diop received her Ph.D in Science and Medical Biotechnologies from the University of Eastern Piedmont in Italy, and after which she joined Medpace as a scientist. Her Ph.D studies were focused on next generation sequencing and Real-time PCR. Medpace is proud to announce that Dr. Diop, together with Dr. Bahassi, will lead the expanding Ph.D leadership team for the molecular suite at Medpace’s Belgium laboratories.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,100 people across 36 countries.

To learn more about Medpace’s central laboratories and how the expansion in Molecular Testing and Genetic Testing can benefit your next clinical trial, contact us.